Stuzenz, they would surely test for this as part of the safety regime inherent in the clinical trials (2A/2B)? There was some mention of filtering out candidates that suffered from bleeding as it could exasperate this condition to some extent? But I dont know enough about the details. Overall it certainly passed the trail and was found to have NO show-stopping side effects. Do your own research, std disclaimers blah.
The competition and their side effects, page-24
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
-0.120(20.9%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 58.5¢ | 60.0¢ | 45.5¢ | $3.512M | 6.826M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 24040 | 45.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.0¢ | 20128 | 2 |
View Market Depth
| Last trade - 16.10pm 28/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
